Bristol Myers Squibb is the only company with two approved CAR T cell therapies with two distinct targets: Breyanzi, which targets CD19, and Abecma, the first approved cell therapy to target BCMA. In addition, arlo-cel is in late development for multiple myeloma and commercial launch preparations have begun. The VP, Global Commercial, Cell Therapy, Hematology, is a critical leadership role acting as general manager of the hematology CAR T portfolio. This position is accountable for the performance of the hematology CAR T assets, working with our marketing affiliates in countries outside the US. The role will be responsible for determining the ex-US strategy and execution to deliver on the CAR T portfolio P&L. This leader will be a key member of the Cell Therapy Commercial leadership team and report directly to the global commercial lead for CAR T.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive